47 terminated. 47 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 47 | Terminated 47 |
| Phase 2 | 10 | Terminated 10 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Terminated | Janssen Research & Development, LLC | 47 | 2024-09-19 | 2026-06-08 |
| SAINT for MDD in an Inpatient Setting Follow-on Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition Active SAINT Stimulation, Sham SAINT Stimulation - Major Depressive Disorder, Major Depressive Episode | Phase 2 / Phase 3 | Terminated | Magnus Medical | 2 | 2024-06-30 | 2025-03-24 |
| A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant Aticaprant, Placebo - Depressive Disorder, Major, Anhedonia | Phase 3 | Terminated | Janssen Research & Development, LLC | 101 | 2024-06-26 | 2026-02-17 |
| Study to Assess the Safety and Effectiveness of NMRA-335140-501 NMRA-335140 - Major Depressive Disorder | Phase 3 | Terminated | Neumora Therapeutics, Inc. | 904 | 2023-11-10 | 2026-09-14 |
| Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD REL-1017, Placebo - Major Depressive Disorder, Depression | Phase 3 | Terminated | Levomecor Inc. | 27 | 2023-08-17 | 2026-07-10 |
| A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) Aticaprant - Depressive Disorder, Major | Phase 3 | Terminated | Janssen Research & Development, LLC | 871 | 2022-09-22 | 2026-10-06 |
| A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) REL-1017, Placebo - Major Depressive Disorder, Depression | Phase 3 | Terminated | Levomecor Inc. | 236 | 2021-03-30 | 2026-07-10 |
| A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy Seltorexant, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | Janssen Research & Development, LLC | 212 | 2020-09-15 | 2025-06-04 |
| A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder SAGE-217, Placebo - Major Depressive Disorder | Phase 3 | Terminated | Biogen | 53 | 2019-08-06 | 2023-11-29 |
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy Ketamine infusion, Midazolam infusion - Major Depressive Disorder | Phase 2 / Phase 3 | Terminated | Yale University | 3 | 2019-07-17 | 2023-04-24 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia SAGE-217, Placebo - Major Depressive Disorder, Insomnia | Phase 3 | Terminated | Biogen | 87 | 2019-02-04 | 2023-11-29 |
| Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD) Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 50 | 2018-10-30 | 2020-07-28 |
| Modafinil's Effects on Cognition in Remitted MDD Modafinil, Placebo - Major Depressive Disorder, Cognitive Impairment | Phase 3 | Terminated | Unity Health Toronto | 9 | 2018-10-15 | 2019-08-08 |
| Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) Rapastinel - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 230 | 2018-08-23 | 2020-07-17 |
| A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) ALKS 5461 - Refractory Major Depressive Disorder | Phase 3 | Terminated | Alkermes, Inc. | 175 | 2018-08-09 | 2021-07-16 |
| Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 363 | 2018-08-02 | 2020-10-09 |
| Study of Rapastinel as Monotherapy in Patients With MDD Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 439 | 2018-06-15 | 2020-09-01 |
| The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder Brexpiprazole, Placebo - Major Depressive Disorder | Phase 3 | Terminated | Otsuka Beijing Research Institute | 65 | 2018-05-30 | 2020-12-29 |
| A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder Duloxetine Hydrochloride - Depressive Disorder | Phase 3 | Terminated | Shionogi | 151 | 2018-01-29 | 2021-06-18 |
Showing 20 of 47. Sign in to see all of them.
Depressive Disorder, Major (37) · Depression (23) · Bipolar Disorder (3) · Anhedonia (2) · Depression, Postpartum (2) · Motor Activity (2) · Sleep Initiation and Maintenance Disorders (2) · Suicidal Ideation (2) · Affective Disorders, Psychotic (1) · Alzheimer Disease (1) · Anemia, Iron-Deficiency (1) · Anxiety Disorders (1) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1)
Mental Disorders (47) · Mood Disorders (47) · Behavior (24) · Behavioral Symptoms (24) · Nervous System Diseases (5) · Bipolar and Related Disorders (3) · Self-Injurious Behavior (3) · Dyssomnias (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Metabolic Diseases (2) · Neurobehavioral Manifestations (2) · Neurocognitive Disorders (2) · Neurologic Manifestations (2) · Nutritional and Metabolic Diseases (2)
Escitalopram (7) · Aripiprazole (4) · GLYX-13 peptide (4) · Aticaprant (3) · brexpiprazole (3) · Exercise (2) · Lithium (2) · Mifepristone (2) · zuranolone (2) · ALKS 5461 (1) · Antidepressive Agents (1) · BTRX-335140 (1) · Celecoxib (1) · Counseling (1) · Desvenlafaxine Succinate (1)
Janssen Research & Development, LLC (4) · Naurex, Inc, an affiliate of Allergan plc (4) · Otsuka Pharmaceutical Development & Commercialization, Inc. (4) · H. Lundbeck A/S (3) · Biogen (2) · Levomecor Inc. (2) · Magnus Medical (2) · Stanford University (2) · University of Texas Southwestern Medical Center (2) · Alkermes, Inc. (1) · Charite University, Berlin, Germany (1) · Eli Lilly and Company (1) · GGZ Buitenamstel (1) · Keming Gao (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1)
United States (32) · Poland (10) · Canada (9) · Germany (7) · Hungary (7) · Bulgaria (6) · France (6) · Spain (6) · Finland (5) · Slovakia (5) · Brazil (4) · Mexico (4) · South Africa (4) · South Korea (4) · Sweden (4)
Jenna Hoogerheyde (4) · Brandon Bentzley, MD (2) · Paul Greene, PhD (2) · Anja Braschoss, MD (1) · Bjorn Backe, MD PhD (1) · Chad D Rethorst, Ph.D. (1) · Claire O'Donovan M O'Donovan, MB FRCPC (1) · Claudia M. Witt, MD (1) · Eus van Someren, PhD (1) · Fredric B Kraemer (1) · Ilie Urlea-Schoen, Dr med (RO) (1)
PMID 18671864, PMID 21199966, PMID 24086352, PMID 26683252, PMID 31307859, PMID 34611902, PMID 34787653, PMID 37244205
2008 (2), 2018 (2), 2009 (1), 2019 (1), 2023 (1), R01MH125160 (1)